• Health Catalyst Invests In healthfinch

    To kick off the third quarter, Health Catalyst has announced its second acquisition of 2020. On July 9, the company announced it acquired healthfinch, Inc. for roughly $40 million. healthfinch provides a workflow integration engine delivering insights and analytics into EMR workflows to automate physicians’ ability to close patient care gaps in... Read More »
  • Second Quarter Healthcare M&A Activity Drops

    The decline in second quarter healthcare M&A probably won’t surprise many of our readers. The second quarter was the first full quarter of healthcare M&A in the shadow of the COVID-19 pandemic, and deal making took a hit as a result, as shown in results from our DSO database. Compared with Q1:20, Q2:20 dropped 20%, with 322 transactions... Read More »
  • Sanofi Inks New Licensing Deal

    Just weeks following its agreement with Translate Bio (NASDAQ: TBIO) for COVID-19 vaccine development, Sanofi (NYSE: SNY) has a new agreement with Kymera Therapeutics Inc. Sanofi and Kymera are signing a multi-program collaboration to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with... Read More »
  • Summit BHC Expands Into West Virginia

    Private equity-backed Summit BHC has announced a new acquisition in West Virginia. The behavioral health treatment company added Highland Hospital to its network for an undisclosed sum. Meridian Behavioral Health Systems, LLC is selling Highland Hospital, an inpatient psychiatric facility (131 beds) with 24 beds dedicated to psychiatric... Read More »
  • Health Care M&A Deals, July 10, 2020

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week based on... Read More »
Biogen Eyes Two Ophthalmic Biosimilars

Biogen Eyes Two Ophthalmic Biosimilars

Boston-based Biogen Inc. (NASDAQ: BIIB) has announced a “proposed transaction” with Samsung Bioepis Co., Ltd. to secure the exclusive rights to commercialize two new ophthalmology biosimilars, SB11 referencing Lucentis® and SB15 referencing Eylea®, in major markets worldwide, including the United States, Canada, Europe, Japan and Australia. In addition, Biogen will acquire exclusive commercialization rights for Samsung Bioepis’ anti-TNF portfolio, including Benepali (etanercept), Flixabi (infliximab) and Imraldi (adalimumab), in China. Biogen will also acquire an option to extend its existing commercial agreement with Samsung Bioepis for this anti-TNF portfolio in Europe.... Read More »

MCOs Make Deals to Combat High Drug Costs

The rising cost of prescription drugs was part of many candidates’ campaign platforms in the 2016 national elections. The topic has not gone away, and is certainly a factor in the dearth of Big Pharma deals in 2017.  Through June 15, M&A in the Pharma sector is down 43%, to 44 transactions, compared with the same period in 2016, which had 77 transactions. Spending is also down in for the first six months of 2017. Through June 15, acquirers announced $19.2 billion in committed financing, down 66% from the same period in 2016, when approximately $56.5 billion was spent. There are deals being done, regarding this issue, but most are not M&A. In fact, several managed care... Read More »

Where Have All the Big Pharma Deals Gone?

The Pharmaceutical sector has experienced a dearth of big deals so far this year. In Q1:16, 40 transactions with pharmaceutical targets were announced, for a total of $46.2 billion. In the first quarter of 2017 (through March 28), only 24 deals (-40%) for pharmaceutical targets have been announced, with a combined total of $10.1 billion (-78%). One factor behind the drop in deals is obvious. The sector came under legislative and consumer scrutiny during the presidential election in 2016, as candidates Hillary Clinton and Donald Trump each decried high prices charged by drug manufacturers, and each vowed to do something about it once elected. President Trump repeated his campaign promise to... Read More »

AbbVie Gets Ahead of the Bad News Curve

On March 11, Sanofi (NYSE: SNY)  and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that an experimental rheumatoid arthritis therapy (salrilumab) helped patients more than AbbVie Inc.’s (NYSE: ABBV) Humira in a late-stage trial. But AbbVie already had a new deal in place, a collaboration with Boehringer Ingelheim, that was announced on March 7. Under terms of the agreement, AbbVie will make an initial upfront payment of $595 million to BI, which will be eligible to receive additional development and regulatory milestone payments and royalties on net sales of any drugs developed from this collaboration. At the center of the deal is BI 655066, an anti-IL-23 antibody now in Phase 3... Read More »